Human Anti-EPOR Recombinant Antibody (clone Ab12) (CAT#: HPAB-1849-FY)

Figure 1 Shows a graph showing equilibrium binding of soluble EpoR with various Ab12 scFv constructs expressed on the surface of yeast cells.

Figure 2 Represents an off-rate analysis of Ab12 41/40 scFv.

Figure 3 Shows a graph of EC50 and Emax values of Ab12, AB12.6 and Ab12.6-related antibodies.

EC50 values represent the concentration of antibody or Epo at which 50% maximal cell proliferation is achieved (50% of the slope of a sigmoidal curve). The Emax values represent the maximum number of cells which this EC50 produces (as measured by absorbance).

Figure 4 Shows a graph showing the formation of CFU-E (colony forming unit-erythroid) from human bone marrow in response to treatment with Epogen, Ab12, Aranesp™, Ab12.6 and isotype control.

Figure 5 Shows a graph showing change in hematocrit in mEpoR-/-, hEpoR+transgenic mice over 28 days after administration of a single dose of Ab12.6 on day 0 versus two doses of Aranesp™ administered on day 0 and day 14.

Compared to Ab12, Ab12.6 had improved potency in elevating and maintaining hematocrit levels over a 28 day time period. Ab12.6 at 0.8 mg/kg also caused a faster rate of rise of hematocrit measured on day 7 than a single dose Aranesp™ administered at 3 μg/kg.

Figure 6 Shows the competition of Ab12 with 125I-labeled EPO for binding to Chinese Hamster Ovary cells expressing recombinant EPO receptor.

Figure 7 Shows the results of an EPO dependent human cell proliferation assay using Ab12 and Ab198.

Figure 8 Shows that Ab12 remains active in inducing the proliferation of F36E cells after storage at 4° C. for up to 20 days.